Table 1 Trends in DDC for different classes of antidiabetic drugs

Insulin and analogues

9.66

9.45

9.64

11.06

11.96

12.23

12.05

12.36

12.99

13.43

0.458(0.342to0.574)^*

Biguanides

1.29

1.24

1.54

1.80

1.93

2.03

2.22

2.47

2.35

0.85

0.060(-0.015to0.194)

Sulfonylureas

1.12

0.99

1.02

1.14

1.36

1.41

1.44

1.46

1.02

0.84

0.005(-0.054to0.064)

Combinations

19.86

24.68

24.17

18.61

22.70

12.07

12.39

11.41

10.73

-1.774(-2.803to-0.745)^*

α-glucosidase

11.16

11.80

12.37

11.19

10.77

10.72

10.56

10.27

2.87

1.60

-0.976(-1.620to-0332)^*

Thiazolidinediones

4.36

4.30

4.34

4.62

4.81

4.91

4.32

4.09

4.08

3.98

-0.042(-0.119to-0.034)

DPP-4i

8.82

8.59

8.02

7.84

6.55

-0.592(-0.870to-0.188)^*

GLP-1RAs

14.40

13.98

11.96

12.53

SGLT2i

8.26

8.41

2.62

2.28

Other

6.90

6.28

6.70

6.45

6.52

6.59

5.75

5.49

5.42

3.10

-0.293(-0.475to-0.110)

Total

6.51

6.89

7.51

7.78

8.19

8.26

6.49

6.48

5.24

4.20

-0.250(-0.532to-0.031)^*